Vaccination against meningococcal disease starts for teens aged 14 to 18 This spring, about 860,000 young people in the Netherlands will receive an invitation for a vaccination against meningococcal disease.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.